Although CDK5 inhibitors have the potential to improve metabolic conditions associated with hypoadiponectinemia, the effects of CDK5 inhibitors on adiponectin biosynthesis has not been fully investigated. The gene discussed is ADIPOQ; the disease is adiponectin deficiency.